
Please try another search
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on TCR2 Therapeutics (NASDAQ:TCRR) Inc on Friday, setting a price target of $58, which is approximately 93.53% above the present share price of $29.97.
Goldstein expects TCR2 Therapeutics Inc to post earnings per share (EPS) of -$0.56 for the first quarter of 2021.
The current consensus among 7 TipRanks analysts is for a Strong Buy rating of shares in TCR2 Therapeutics, with an average price target of $48.43.
The analysts price targets range from a high of $65 to a low of $37.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $0 and a net profit of -$17.19 million. The company's market cap is $1 billion.
According to TipRanks.com, Mizuho Securities analyst Mara Goldstein is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 18.6% and a 44.64% success rate.
TCR2 Therapeutics, Inc. is an immunotherapy company, which develops biological drugs and engineering T-cells for cancer therapy. The company offers cancer therapy, T-cell biology, Immunology and Molecular biology. It also engages in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded in May 2015 and is headquartered in Cambridge, MA.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.